Literature DB >> 9539336

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.

M Gassen1, A Gross, M B Youdim.   

Abstract

A significant body of evidence has been provided to support the hypothesis that oxidant stress may be responsible for the degeneration of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease. Apomorphine, a dopamine D1/D2-receptor agonist in the clinical therapy of Parkinson's disease, has been found to be a potent antioxidant and to prevent free radical reaction in rat brain mitochondrial fraction. In this article we show that 1-10 microM of apomorphine protects rat pheochromocytoma (PC12) cells from the toxic effects of H2O2 (0.6 mM) and the neurotoxin 6-hydroxydopamine (150 microM). These effects were not exhibited by ascorbic acid, desferal, lisuride, or bromocriptine. Although pergolide exhibited some protection of PC12 cells against H2O2 toxicity, it was not as potent as apomorphine. In light of the present findings and the clinical reports that parkinsonian patients on long-term apomorphine stabilize clinically and can be weaned off L-dopa, one may assume that apomorphine can exert a neuroprotective activity via its potent antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539336     DOI: 10.1002/mds.870130208

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

3.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase.

Authors:  Liping Ma; Jiawei Zhou
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

6.  Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties.

Authors:  Orly Weinreb; Tamar Amit; Silvia Mandel; Moussa B H Youdim
Journal:  Genes Nutr       Date:  2009-09-10       Impact factor: 5.523

7.  The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.

Authors:  M B H Youdim; E Grünblatt; S Mandel
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 8.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

9.  Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells.

Authors:  Wei-Guo Liu; Yan Chen; Biao Li; Guo-Qiang Lu; Sheng-Di Chen
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.